OGI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Organigram Global Inc (OGI) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite short-term technical weakness, the company's strong financial performance, positive analyst ratings, and growth in revenue and EBITDA make it a compelling long-term investment opportunity.
The technical indicators show bearish momentum with MACD below 0 and negatively expanding, RSI at 22.738 in the neutral zone, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 1.319 and S2 at 1.232, indicating near-term weakness.
Q1 revenue increased by 48.7% YoY to $63.5 million, exceeding market expectations.
Adjusted EBITDA improved by 273% YoY to $5.3 million.
Net income turned positive at $20 million, a significant improvement from a net loss of $27.5 million last year.
Analysts maintain a Buy rating with price targets of C$3 and C$4, citing strong domestic and international sales growth and margin expansion.
Technical indicators suggest short-term bearish momentum.
The stock has a 60% chance to decline in the next day and week based on candlestick pattern analysis.
Regulatory headwinds and structural inefficiencies in the Canadian cannabis market could pose challenges.
In Q1 2026, Organigram reported a 48.7% YoY revenue increase to $63.5 million, a net income of $20 million (a turnaround from a $27.5 million loss), and a 273% YoY improvement in adjusted EBITDA to $5.3 million. Gross margin also increased significantly by 324.49% YoY to 10.4.
Analysts have a positive outlook on Organigram, with Canaccord initiating coverage with a Buy rating and a C$3 price target, and Alliance Global raising its price target to C$4. Analysts highlight the company's strong momentum, market-leading positions, and strategic relationship with BAT as key drivers of growth.
